Delivery Order SPE2DB24D1021-SPE2DB25FEZSC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This competitively awarded, firm fixed-price delivery order is set to be completed by September 8, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery order issued under a larger contract vehicle rather than a standalone...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $4,712.76, with completion targeted for September 10, 2025. This non-set-aside award represents a competitive procurement of pharmaceutical products to support federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier within the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,718.48. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 1 mg tablets in a 30-count package, with a ceiling value of $1,553.40 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of October 6, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical product will be performed and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Envarsus XR 1 mg tablets (100 count) with a ceiling value of $3,430.43. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-set-aside, competitively awarded contract. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) valued at $1,711.95. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by October 6, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction supporting...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $2,148.10. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 0.75 mg tablets (30-count) with a ceiling value of $2,339.52. This delivery order represents a competitive, firm fixed-price procurement with no set-aside designation and is scheduled for ultimate completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count units) on August 7, 2025, with completion expected by August 28, 2025. This firm fixed price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division, with performance to be executed from the company's Conshohocken, Pennsylvania headquarters. The contract falls under...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZSCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 tablets, with a contract ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's portfolio with the Defense Logistics Agency encompasses a comprehensive range of pharmaceutical products including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative is planning to establish multiple regional contracts with separate contractors, positioning AmerisourceBergen to continue serving various federal healthcare customers including the Defense Health Agency and U.S. Coast Guard through this flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/15/25 |